Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or Psoriatic Arthritis (PsA) in Spain

• Status: Completed
• Trial end date: 2006-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety of etanercept in patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) or psoriatic arthritis (PsA) in Spain

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Etanercept

Criteria

Inclusion Criteria:

• RA or PsA in whom DMARDs/antiTNF antibodies/anti IL1 has been insufficient or inappropriate

• Children from 4 to 17 years old with JIA polyarticular

Exclusion Criteria:

• Clinically significant abnormal screening lab values

• Patients who are planning to undergo elective surgery during the study period.

• Other current autoimmune connective tissue diseases